As one of the nation’s most vital health care safety net programs, Medicaid provides health coverage for more than 72 million Americans. And all states cover optional outpatient prescription drugs. The Medicaid Drug Rebate program covers FDA-approved prescription drugs in exchange for rebates to states from manufacturers.
While curative drug treatments are an important part of the health care that individuals receive, rising costs and gaps in the process hinder state Medicaid programs’ ability to affordably access newer treatments. Federal pharmacy policies must consider the impact of these challenges on Medicaid programs and patients who need critical breakthrough drugs.
As the voice for state Medicaid directors in national policy discussions, NAMD is actively engaged in ongoing discussions with federal policymakers and stakeholders on these issues. NAMD also supports a group of pharmacy policy and technical experts to address critical priorities and gaps for Medicaid pharmacy programs.
NAMD has reviewed many Medicaid drug rebate and pharmacy-related proposals and released memos and letters to policymakers to on pharmaceutical issues including the role of genetic drugs, coordination between institutions like CMS and the FDA, and the voices of states and their Medicaid programs in the face of increasing drug and treatment prices.